A study of gabapentin in the treatment of tonic-clonic seizures of alcohol withdrawal syndrome.
In this study for thirty (30) patients with alcohol withdrawal syndrome, the response to anticolvusant gabapentin was assessed. Thirty (30) patients with median age of 57.0 years and median body weight of 79.1 kg were treated with gabapentin 3 x 300 mg daily for up 30 days. The preliminary findings of this study suggest that gabapentin is very effective against tonic-clonic seizures in alcohol withdrawal syndrome. Gabapentin was safe and well tolerated. For twenty (20) patients no side effect were observed.
Rustembegovic
Avdo
A
Anton Proksch Institute of Drug and Alcohol Dependence, Vienna, Austria.
Sofic
Emin
E
Tahirović
Ismet
I
Kundurović
Zlata
Z
D000085:Acetates / Q000627:therapeutic use*; D020270:Alcohol Withdrawal Seizures / Q000188:drug therapy*; D000588:Amines; D000927:Anticonvulsants / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008297:Male; D008875:Middle Aged; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin